We held 1st China Pharma IP Summit 2016 on 17-18, November last year and confirmed more than 190 attendees from government agencies, in-house IP counsel, IP law firms, agencies and solution providers. The development of pharmaceutical industry heavily relies on their IP strategies, and this year pharmaceutical IP protection in China is drawing more attentions than before. Firstly, on 12th May 2017, the China Food and Drug Administration issued a proposal ( called 2017 Policy Notice No.55), which proposes to establish the patent linkage and amend the regulatory data protection regime. In the Notice No.55, it indicates the procedures of patent linkage and changes of regulatory data protection. Secondly, China is studying the drug patent extension reform, and the result may come out within this year. Additionally, the SIPO is amending PATENT LAW OF THE PEOPLE'S REPUBLIC OF CHINA and the new amendments to SIPO's Guidelines for Patent Examination has been effective since 1st April, 2017.

Based on above we will launch 2nd China Pharma IP Summit 2017 on 7th -8th December this year in Shanghai, and continue to provide a networking platform for industry peers.

Through the event, you can:

1. Follow updated policies in China, including patent linkage, regulatory data protection, patent extension reform, and the changes of Patent Law and Guidelines for Patent Examination.

2. Understand the latest examination standards and litigation proceedings in US and Europe

3. Learn excellent IP management cases

4. Meet you client fact to face and interacts with industry peers

The participants are mainly from pharma companies, biotech companies, law firms, IP/patent agencies, IP/patent solution providers, governments, relevant associations, research institutes. If you would like to attend or sponsor our summit, please feel free to call / email us to reserve your seats ASAP!

Thanks again for your attention and looking forward to your participation!


DAY 1 Morning

0730 Registration Open


Opening Remark

Day1 Chairman: Tony Chen, Partner, Jones Day


Managing Global IP Strategy & Team--Practical Insights

John D. Conway, Senior Vice President and Global Head of Intellectual Property, Sanofi


505(b)(2) NDAs v. ANDAs: Case Studies and Implications for Patent Portfolio Development and US Litigation

Christopher T. Griffith, Founding Partner, Green, Griffith & Borg-Breen LLP

Coffee Break


Interpretation of Specific Pharmaceutical Intellectual Property Policies in China

Qingkui Zhang, Director, Pharmaceutical IP Research Committee of Chinese Pharmaceutical Association


Drug Patent Extension Reform in China--From a Perspective of China Innovative Drugs Status

Li Chen, Co-founder and CEO, Hua Medicine (Shanghai) Ltd


Panel Discussion: Rules For The Implementation of Patent Linkage in China


Tony Chen, Partner, Jones Day


Randall Rader, Former Chief Judge, the United States Court of Appeals for the Federal Circuit

Chen Li, Co-founder and CEO, Hua Medicine (Shanghai) Ltd

Cheng Yongshun, Director, Beijing Intellectual Property Institute (Former Senior Judge and the

Deputy Presiding Judge of the IP Division of Beijing High People’s Court)

1240 Lunch Buffet

DAY 1 Afternoon


Patent Acquisition: Due Diligence Issues

Alyson Wooten, Senior Associate, Kilpatrick Townsend & Stockton LLP


Patent Invalidation Case Study

Chen Zhefeng, Senior Patent Attorney, Prosecution Department of Chemistry, Shanghai Patent & Trademark Law Office, LLC


Coffee Break


Topic is Confirming

Wu Li, AnJie Law Firm


Regulatory Data Protection Regime Changes in China and Impacts

Chen Bing, Associate Dean, China Food and Drug Administration Insititute of Executive Development;Deputy Director of Pharmaceutical IP Research Committee of Chinese Pharmaceutical Association


Panel Discussion: Hotspot Issues of Pharmaceutical Patent and What Can We Learn?


Heather Lin, Senior Partner and Patent Attorney, NTD Intellectual Property Attorneys


Alvin Deng, Head of Intellectual Property, Novozymes China

Li Renjiu, Senior Patent Director, Luye Pharma Group Ltd

Christopher Shaowei, Senior Partner, NTD Patent & Trademark Agency

Ge Yongqi, Deputy Director of The First

1820 End of Day 1

DAY 2 Morning


Chairman Opening Remark

Wang Ningling, Shanghai Office Managing Partner, Finnegan, Henderson, Farabow,Garrett & Dunner, LLP


The Latest Developments of Patenting Pharmaceutical and Biotechnological Inventions at the EPO

The speaker will build up on his last year’s presentation and update more specifically on new case law and practice as regards patentability requirements for pharmaceuticals and biotechnological inventions, including the recent changes to the implementing regulations in respect of plant patenting. He will also update on other EPO developments such as the new opposition practice, IP5 developments (global dossier, extension of validation states and PPH)

Dieter Tzschoppe, Director Operations for Biotechnology / Pure and Applied Organic Chemistry, European Patent Office


Generic Product Launches - Preparing Strategies Which Address Global IP and Regulatory Issues

Yehudah Livneh, Strategic IP consultant; Former General Patent Counsel and VP Corporate IP and Legislative Affairs at Teva Pharmaceuticals


Patent Litigation in Europe With Emphasis on Germany Including A Case Study (Zhejiang Medicines Co., Ltd. vs. Kaneka "Coenzyme Q10)

Dr. Ute Kilger and Dr. Markus Engelhard, BOEHMERT & BOEHMERT

1030 Coffee Break


State of Play of Biosimilars in the Europe

History of development and registration

Dealing with exclusivity / patent litigation

Marketing strategies

Christof Bull, Associate General Patent Counsel, UCB Biopharma


Panel Discussion:The US Supreme Court Ruling on Amgen vs. Sandoz Case And What Developers Need To Know?


Wang Ningling, Shanghai Office Managing Partner, Finnegan, Henderson, Farabow,Garrett & Dunner, LLP


Dipak Mundra, Partner, LexOrbis

Joo Mee Kim, Member, Rothwell Figg

Stephen Auten, Partner, Taft Stettinius & Hollister LLP

Yang Yieyie, Associate, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

1230 Lunch Buffet

DAY 2 Afternoon


The Fact Investigating And Evidence Determination in Pharmaceutical Patent Infringement Lawsuits

Yongqi Ge, Deputy Director of The First Administrative Proceedings Division, Patent Reexamination Board of SIPO


Patent Management Case Study---- From R&D To Launch

Xu Shuwen, Legal Director, Guangzhou Baiyun Mountain Pharmaceutical Factory

1510 Coffee Break


Hatch-Waxman Act: Balancing Innovation and Affordable Drugs

Randall R. Rader, Chief Judge (Ret.), U.S. Court of Appeals for the Federal Circuit


Hot Issues and Growing Trend of Pharmaceutical Patent Litigation in China--From a Perspective of Judicial Trial

Yunchuan Zhou, Of Counsel, Jones Day; Former IP Judge at the Supreme People's Court of China

Xiangjian Ying, SVP, IPHOUSE; Former Judge at Zhejiang Provincial Higher People's Court

1650 Closing Remark


  Media Partner